This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Yaksh, T. L. Articles by Allen, J. W. Search for Related Content PubMed PubMed Citation Articles by Yaksh, T. L. Articles by Allen, J. W. Related Collections Regional Anesthesia Pain Pharmacology

---

PAIN MEDICINE

The Use of Intrathecal Midazolam in Humans: A Case Study of Process

Department of Anesthesiology, University of California, San Diego, La Jolla, California

Address correspondence and reprint requests to Tony L. Yaksh, PhD, Department of Anesthesiology 0818, University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093-0818. Address e-mail to tyaksh{at}ucsd.edu

Early preclinical work demonstrated the potential role of spinal benzodiazepine pharmacology in regulating spinal nociceptive transmission. We review this preclinical activity and the evolving implementation of intrathecal midazolam in humans for pain management. Important elements in this development for use in humans are issues pertinent to safety and the preclinical reports that have increased our understanding of intrathecal midazolam toxicity. We seek to emphasize the time course of these studies and how they merged to provide enabling data that drove the clinical implementation. In the case of midazolam, we point to the potential issues that arose when preclinical safety data were unreasonably ignored and how consideration of preclinical safety data can serve to facilitate drug development by demonstrating reasonable safety profiles that document the minimal degree of potential risk to the patient. Issues that are of continuing relevance to the use of intrathecal midazolam, including issues of formulation and kinetics, are considered.

IMPLICATIONS:The intrathecal use of midazolam has evolved over 20 years though a combination of preclinical and clinical investigations. We review the time course of this development to define critical elements that should be pursued in reducing the risk associated with the clinical use of a novel spinal drug.

This article has been cited by other articles:

				Y. K. Batra, R. Mahajan, S. Kumar, S. Rajeev, and M. Singh Dhillon A Dose-Ranging Study of Intraarticular Midazolam for Pain Relief After Knee Arthroscopy Anesth. Analg., August 1, 2008; 107(2): 669 - 672. [Abstract] [Full Text] [PDF]

				M. A. Duncan Labour pains Can Fam Physician, January 1, 2008; 54(1): 28 - 29. [Full Text] [PDF]

				S. L. Shafer Anesthesia & Analgesia's Policy on Off-Label Drug Administration in Clinical Trials Anesth. Analg., July 1, 2007; 105(1): 13 - 15. [Full Text] [PDF]

				S. K. Lin More on the Dilemma of Intrathecal Midazolam Anesth. Analg., February 1, 2005; 100(2): 604 - 604. [Full Text] [PDF]

				G. A. Van Norman, S. K. Palmer, and S. H. Jackson The Ethical Role of Medical Journal Editors Anesth. Analg., February 1, 2005; 100(2): 603 - 604. [Full Text] [PDF]

				M. J. Cousins and R. D. Miller Intrathecal Midazolam: An Ethical Editorial Dilemma Anesth. Analg., June 1, 2004; 98(6): 1507 - 1508. [Full Text] [PDF]

				T. L. Yaksh and J. W. Allen Preclinical Insights into the Implementation of Intrathecal Midazolam: A Cautionary Tale Anesth. Analg., June 1, 2004; 98(6): 1509 - 1511. [Full Text] [PDF]